Hofseth BioCare ASA: Key Information Relating to Subsequent Offering

Core Viewpoint - Hofseth BioCare ASA ("HBC" or "the Company") is conducting a Subsequent Offering to raise gross proceeds of approximately NOK 30 million by issuing up to 16,666,666 new shares at a subscription price of NOK 1.80 per share, which is the same as the offer price in the recent Private Placement [2][3]. Subsequent Offering Details - The Subsequent Offering is conditional upon the approval of the Company's extraordinary general meeting (EGM) scheduled for around 20 November 2025, which will authorize the board of directors to issue shares [3][4]. - The offering is directed towards shareholders as of 24 October 2025, excluding those who participated in the Private Placement and those in jurisdictions where the offering would be unlawful [4]. - If Eligible Shareholders do not subscribe for all available shares, remaining shares may be allocated to Secondary Subscribers deemed strategically important by the Board [4][5]. - The subscription period will begin following the publication of an offering prospectus, and the Company reserves the right to cancel the offering if the shares trade at or below the offer price in significant volumes [5][6]. Important Dates and Information - Date of approval for the Subsequent Offering: On or about 20 November 2025 [4]. - Last day including right: 24 October 2025 [6]. - Ex-date: 27 October 2025 [6]. - Record date: 28 October 2025 [6]. - Maximum number of new shares to be issued: 16,666,666 [6]. - Subscription price per share: NOK 1.80 [6].